REG - Competition and Mkts - Merger Update: Cochlear / Oticon

Demant A/SAnnouncement

11/10/2022 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221011:nRSK3696Ca&default-theme=true

RNS Number : 3696C  Competition and Markets Authority  11 October 2022

Anticipated acquisition by Cochlear Limited of the hearing implants division
of Demant A/S, known as Oticon Medical

Invitation to comment: Closes on 25 October 2022

On 11 October 2022, the CMA launched its phase 1 merger investigation into the
anticipated acquisition by Cochlear Limited of the hearing implants division
of Demant A/S, known as Oticon Medical

The CMA is considering whether it is or may be the case that this transaction
if carried into effect, will result in the creation of a relevant merger
situation under the merger provisions of the Enterprise Act 2002 and, if so,
whether the creation of that may be expected to result, in a substantial
lessening of competition within any market or markets in the United Kingdom
for goods or services.

To assist it with this assessment the CMA invites comments on the transaction
from any interested party.

These comments should be provided by the deadline set out above to:

Principal case officer: Lavinia de Havilland

Tel no: 0203 738 6385 / E-mail: Lavinia.deHavilland@cma.gov.uk
(mailto:Lavinia.deHavilland@cma.gov.uk)

Case officer: Daniel Norcott

Tel no: 0203 738 6353 / E-mail: Daniel.Norcott@cma.gov.uk
(mailto:Daniel.Norcott@cma.gov.uk)

Your name and contact details are your personal data. In collecting,
receiving, storing, accessing and using your personal data, the CMA, as
controller, is processing your personal data. The CMA processes personal data
in accordance with data protection law. The CMA is processing your personal
data so that it can contact you again, should it need further help or
information from you, in order to carry out its merger work under Part 3 of
the Enterprise Act 2002. For more information about how the CMA processes
personal data and your rights relating to that data, please see our Privacy
Notice
(https://www.gov.uk/government/organisations/competition-and-markets-authority/about/personal-information-charter)
 .

For further information on the CMA's role after Brexit please see
our Information for businesses on the CMA's role after Brexit
(https://www.gov.uk/government/collections/cmas-role-after-brexit)
 collection.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MERBKKBDBBDDNKD